APC Streptavidin (High Concentration)

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Allophycocyanin, SAv-APC
Cat # Size Price Quantity Check Availability
405243 500 µg $350.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-APC is useful for detecting biotinylated antibodies. The excitation of APC by 600-635 nm laser light induces a fluorescence emission maximum of 660 nm.

Technical data sheet

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with APC under optimal conditions.
Concentration
1.0 mg/ml
Storage & Handling
The Streptavidin-APC solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified

Recommended Usage

Each lot of this Streptavidin-APC is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the APC conjugation. For immunofluorescent staining, the recommended use of this reagent is ≤ 0.06 µg per million cells in 100 µl staining volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Streptavidin-Allophycocyanin (APC) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-APC is 320 kD and Streptavidin alone is 52 kD.

Application References

(PubMed link indicates BioLegend citation)
  1. Kamimura D, et al. 2006. J. Immunol. 177:306.
  2. Andoniou CE, et al. 2005. Nature Immunology 6:1011.
  3. Chou WC,et al.2006.Blood108:3005. PubMed
  4. Malagolini N, et al. 2009. Glycobiology. 19:172. PubMed
  5. Kroeger KM, et al. 2009. J. Leukocyte Biol. PubMed
  6. Imada M, et al. 2009. Int. Immunol. 21:1151. PubMed
  7. Yi Y, et al. 2010 J. Biol Chem. 285:21233. PubMed
  8. King IL, et al. 2010. J. Immunol. 185:6138. PubMed
  9. Yokoyama T, et al. 2011. Int Immunol. PubMed
  10. Rusert P, et al. 2011. J. Exp Med. 208:1419. PubMed
  11. Bollig N, et al. 2012. PNAS. 109:8664. PubMed
  12. Nguyen V, et al. 2012. J. Immunol. 189:1081. PubMed
  13. Jager NA, et al. 2012. J Nucl Med. 53:1229. PubMed
  14. Liberman AC, et al. 2012. Mol Immunol. 50:220. PubMed
  15. Ogawa H, et al. 2012. Biochem Biophys Res Commun. 420:114. PubMed
  16. Ludin A, et al.2012. Nat Immunol. 13:1072. PubMed
  17. Sugiura D, et al. 2012. PLoS One. 7:e44770. PubMed
  18. Tani-Ichi S, et al. 2012. PNAS. 110:612. PubMed
  19. Jin L, et al. 2013. PNAS. 110:3907. PubMed
  20. Ota T, et al. 2013. J. Immunol. 191:3179. PubMed
  21. Fu X, et al. 2013. PNAS. 110:17982. PubMed
  22. Ryan SO, et al. 2014. Glycobiology. 24:362. PubMed
  23. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  24. Pilling D, et al. 2014. PLoS One. 9:93730. PubMed
  25. Matthews JA, et al. 2014. PLoS One. 9:97707. PubMed
  26. Owen KA, et al. 2014. PLoS Pathog. 10:1004159. PubMed
  27. Duek A, et al. 2014. Blood. 123:3943. PubMed
  28. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
Product Citations
  1. Yu H, et al. 2023. Nat Commun. 14:1058. PubMed
  2. Kristensen NP, et al. 2022. J Clin Invest. 132:. PubMed
  3. Kim DJ, et al. 2020. J Virol. :94. PubMed
  4. Brunk F, et al. 2021. Eur J Immunol. 51:2651. PubMed
  5. Han Y, et al. 2019. J Clin Invest. 130:26. PubMed
Go To Top Version: 3    Revision Date: 06/18/2019

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

Login/Register
Forgot your password? Reset Password
Request an Account